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Abstract
Background: Poor asthma control observed in several surveys may be related to a lack of systematic assessment
by physicians and/or to patient underestimation of symptoms. Along this line, the purpose of this study was to
investigate the level of asthma control in patients attending the GP office for different reasons, either for renewal
of drug prescription or for worsening of asthma symptoms.
Methods: Each of the 145 General Practitioners (GP) in Italy and Spain selected at least eight asthmatic patients
attending their office for a renewal of drug prescription (Group A) or for worsening of asthma symptoms (Group B),
between May and December 2009. Asthma Control Test (ACT) and other clinical information (including SF-12
questionnaire) were collected.
Results: Data from 1375 patients with moderate-severe asthma were analysed (mean age: 47.2 years; female: 59%;
smokers or ex-smokers: 35.4%); 57% were on treatment with ICS-LABA combination. ACT score < 20 (uncontrolled
asthma) was observed in 77.8% Group B patients, as expected, but also in 28.6% Group A patients. Uncontrolled
patients reported their asthma being well or fairly well controlled in 68.4% of cases. Risk factors for uncontrolled
asthma were older age, asthma severity, and smoking habit. In uncontrolled patients, GPs changed or increased
the level of therapy in 75.8% and initiated asthma treatment in 61.3% of cases, in association with educational
intervention, closer monitoring or pulmonologist consultations.
Discussion: The systematic use of ACT in asthmatics attending GP’s clinic may detect high rates of uncontrolled
patients who underestimate their clinical conditions, particularly those asking solely for asthma medication renewal.
Poor adherence to daily drug therapy was reported in more than 40% of patients and could be an important
contributor of uncontrolled asthma.
Conclusions: The results highlight the importance of routine longitudinal assessment of asthma patients in primary
care and point to the need for an increased attention to asthma management by GPs.
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Background
Although Global Initiative for Asthma (GINA) provides
guidelines for optimal management of asthma [1] in
order to reach and maintain good control of the disease,
several observational studies show that the majority of
asthmatic patients are not controlled. The Asthma in
Reality in Europe (AIRE) study, based on telephone
interviews to a large group of patients, showed that only
5.3% of the surveyed population fulfilled all criteria of
asthma control as indicated by the GINA guidelines;
furthermore, approximately 50% of patients considered
their asthma to be completely or well controlled despite
reporting severe persistent symptoms [2], thus showing
large discrepancy between patients’ perception of control
and actual severity of the disease. More recently, an
internet-based survey confirmed that asthmatic patients
tend to overestimate their asthma control, with 55% of
them reporting several limitations in daily life activities
despite frequent visits to General Practitioners (GPs) [3].
Finally, a large study performed in primary care settings
reported that asthma control in Italy was not optimal,
with many patients requiring unscheduled GP visits,
Emergency Room attendance and hospitalization be-
cause of asthma [4].
The reasons why reaching good asthma control is still
so difficult are various, including inappropriate pharma-
cologic treatment and poor adherence to the asthma
management plan. The latter may be related to the
attitude of many patients to underestimate symptom se-
verity and frequency, refusing regular therapy when
symptoms are mild or absent. These considerations sug-
gest that greater attention to the level of asthma control
should be paid by both patients and physicians, possibly
with the help of simple and accurate tools. For this rea-
son the Asthma Control Test (ACT) has been developed
and validated. This simple 5-item questionnaire allows
computing a single score which reflects the symptom
control domain of asthma control. This tool may in-
crease the patient’s awareness of asthma control, allow-
ing to monitor the outcome of the disease and helping
the patients to understand when a consultation with the
physician is needed [5, 6]. In combination with spirom-
etry and Peak Expiratory Flow (PEF) monitoring, ACT
may represent an important tool for GPs for monitoring
and adjusting pharmacologic treatment.
In clinical practice, asthmatic patients usually consult
their GPs for two main reasons: asthma deterioration
(in order to review their current therapy) or prescrip-
tion renewal regardless of asthma control. Checking the
level of asthma control in seemingly stable patients, at-
tending the GP clinic only for prescription renewal,
may be a good opportunity to evaluate asthma control,
health-related quality of life and health resource
utilization.
The ACTIS study (Asthma Control Test study in Italy
and Spain) was performed in two European countries
(Italy and Spain) with the main objective of evaluating the
level of asthma control in a sample of asthmatic patients
spontaneously attending the GP clinic for different rea-
sons. The hypothesis was to find out whether patients re-
ferring to GPs for a simple renewal of drug prescription
had actually poor asthma control. In these patients GPs
usually confirm the previous treatment, with no further
assessment of their asthma; in these cases, ACT evalu-
ation may provide useful information for home-based
management, allowing early detection of asthma deterior-
ation or poor asthma control not properly perceived by
the patients. Furthermore, we evaluate the relationship
between asthma control and risk factors as well as the
mental and physical components of the health status.
Methods
ACTIS (GSK study 111595) is a multicenter and multi-
national (Italy and Spain) observational cross-sectional
study, performed in GP’s offices.
The study was approved by the Ethic Committees and
all the patients provided written informed consent.
The primary objective was the evaluation of the preva-
lence of uncontrolled asthma (defined as an ACT score
< 20) in two different populations: a) patients attending
the GP’s clinic only for prescription renewal of currently
used anti-asthmatic drugs (Group A); b) patients attend-
ing the GP’s clinic for asthma symptom worsening
(Group B). Secondary objectives were the assessment of
health-related quality of life (by SF-12 questionnaire),
consumption of disease-related healthcare resources in
the previous 6 months (in particular, loss of working
days, GP’s or pulmonary specialist’s visits, Emergency
Room attendance or hospitalization for asthma), adher-
ence to therapy.
Study design
One hundred forty five GPs in Italy and Spain voluntar-
ily agreed to participate to the study, which was per-
formed from May 2009 to December 2009. Each GP was
to recruit at least eight patients with known diagnosis of
asthma, consecutively attending their clinic for one of
these two reasons: 1) renewal of drug prescription
(Group A, at least 4 patients per GP); 2) recent worsen-
ing of asthma symptoms requiring a change in current
treatment (Group B, at least 4 patients per GP).
Inclusion criteria were: male or female with age ≥
18 years, asthma diagnosed at least 6 months before the
study (with or without having performed pulmonary
function tests), ability to understand and fill the ques-
tionnaires used in the study, and willing to sign the in-
formed consent for the participation to the study and
the use of personal data. Exclusion criteria were mainly
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the presence of pulmonary diseases other than asthma
(like COPD or bronchiectasias) or other severe cardio-
vascular or metabolic diseases.
Patients were administered by GPs: a) Asthma Control
Test (ACT); b) SF-12 (only to the Italian sample of pa-
tients), a shortened and validated version of the SF-36
questionnaire, exploring health-related quality of life by
computing two indices, one related to physical status
and one related to mental status; a higher score indicates
a better physical or mental status [7]; c) a 4-item ques-
tionnaire, called Morinsky-Green (validated and well
known), aimed at investigating patient’s compliance with
treatment, specifically if patients stop taking their medi-
cines when they feel better (only in the Spanish sample
of patients).
Each GP filled an electronic record form, which in-
cluded information on patient clinical history, asthma
severity, current therapy, healthcare resource consump-
tion in the last 6 months (GP’s or pulmonary specialist’s
visits, Emergency Room attendance, hospitalizations for
asthma), as well as general data (age, gender, smoking
habit, etc.).
GPs then evaluated the results of ACT and assessed
whether current therapy was adequate to the level of
asthma control. Treatment was consequently modified
and the new prescription was recorded.
The protocol was approved by local Ethic Committees
and written informed consent was obtained from each
patient before the inclusion into the study.
Statistical analysis
The analyses performed were mainly descriptive: mean,
standard deviation, median, range and quartiles were
reported for numerical variables; absolute values and
percentages were computed for qualitative variables.
Missing values were excluded for both numerical and
qualitative variables.
Univariate logistic analyses have been performed to
study the relationship between some independent vari-
ables (such as age, gender, asthma severity, duration of the
disease) and ACT score as dependent variable. Analysis of
variance (ANOVA) was performed to evaluate differences
between groups for the above mentioned independent
variables, for markers of health resource consumption
(loss of work days, number of visits to GP, etc.) and of
quality of life as assessed by SF-12 questionnaire.
Results
The ACTIS study involved 145 GPs. Overall, 1375
patients were recruited: 56% attended the GP’s clinic for
renewal of drug prescription (Group A) and 44% for
worsening of asthma symptoms (Group B).
Main characteristics of the enrolled patients
Table 1 shows patient demographic and clinical findings:
40.7% were male, mean age 47.2 years. Mean age at the
onset of asthma was about 30 years: in 26.8% of cases
asthma begun in childhood or adolescence, whereas in
7.2% after 60 years. The clinical diagnosis of asthma was
confirmed by functional tests (spirometry with/without
methacholine challenge) in 56.1% of the subjects, and
the time span since the last spirometry was of about
2 years in both groups. The majority of patients were on
inhaled corticosteroid/long-acting beta2-agonist (ICS/
LABA) combinations. There was no significant differ-
ence between patients from Group A and patients from
Group B with regard to anthropometric findings, general
characteristics of the disease (duration of asthma, per-
formance of spirometry) and type of pharmacologic
treatment. Also, the characteristics of the recruited sub-
jects in Italy and Spain were similar.
The control of asthma using ACT
Subjects with uncontrolled asthma (ACT < 20) were
about 50% of the whole study population. As expected,
in Group B (patients with symptom worsening) the
percentage of uncontrolled asthma was high (77.8%);
however, even in Group A (patients asking for renewal
of drug prescription) 28.6% of patients showed uncon-
trolled asthma. The difference between the two groups
was statistically significant (p < 0.0001 by chi-square test)
(Fig. 1).
When asked about perception of their level of asthma
control, patients with uncontrolled asthma reported to be
well or fully controlled in 20% of cases, and partially con-
trolled in 48% of cases. Only a minority of these patients
(31.4%) believed that their asthma was poorly controlled.
In the univariate analysis, lack of control significantly cor-
related with age (Odds Ratio, OR = 1.216), asthma severity
(OR = 3.413), smoking habit (smokers vs ex- and non-
smokers: OR = 1.474), duration of asthma (OR = 1.092)
and country (Italy vs Spain OR = 1.469) (Table 2). Further-
more, Group B patients reported a higher rate of loss of
working days, consultations to GP, visits to ER or hospital-
izations than Group A patients (data not shown).
Quality of life measured by the SF-12 questionnaire
The SF-12 questionnaire was administered to the Italian
sample of patients. The physical component score derived
from the SF-12 questionnaire was lower in patients from
Group B than in patients from Group A (40.5 vs 46.8, p <
0.001) and in patients with uncontrolled asthma than in
those with ACT score ≥ 20 (39.6 and 49.2 respectively, p <
0.001). Same trends for Group B vs Group A (43.5 vs 48.1,
p < 0.001) and for uncontrolled vs controlled asthmatics
(43.4 vs 49.1 respectively, p < 0.001) were observed for the
mental component score. In a multivariate analysis, both
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physical and mental component scores were greater (indi-
cating a better quality of life) in patients with good or total
asthma control, in younger patients, in those with less
severe asthma and in those with shorter duration of the
disease (the latter only for the physical component).
Compliance to drug therapy
There is no difference in the two groups in the percentage
of patients that at times forget to take their medications
(39.9% in group A and 47.3% in group B). However, the
number of patients who abandon the treatment when they
feel better is significantly higher in patients from Group B
than in patients from Group A: 47.6% vs 58% (Chi-square
0.012) (Fig. 2).
Therapeutic decisions of GPs after the assessment of
control
Table 3 and Fig. 3 report the actions undertaken by GPs
when presented with a patient who had poor asthma con-
trol. In 40.1% of cases GPs changed the level of therapy
Table 1 Demographics and main characteristics of the recruited asthmatic patients
Reasons for GP consultation
Total A:
Asking for asthma drugs
prescription renewal
B:
seeking for medical advice
due to symptom worsening
Total (n) 1375 777 598
Male (n, %) 560 (40.7) 313 (40.3) 247 (41.3)
Female (n, %) 815 (59.3) 464 (59.7) 351 (58.7)
Age (mean, SD) 47.2 (17.6) 46.0 (17.7) 48.7 (17.4)
Smoking habits
• non smoker 888 (64.6) 522 (67.2) 366 (61.2)
• smoker 265 (19.3) 130 (16.7) 135 (22.6)
• ex smoker 222 (16,1) 125 (16,1) 97 (16.2)
Mean duration of asthma (years, SD) 12.8 (10.1) 12.6 (9.9) 13.0 (10.4)
Clinical diagnosis (n, %) 604 (43.9) 349 (44.9) 255 (42.6)
Spirometry test (n, %) 771 (56.1) 428 (55.1) 343 (57.4)
Time to last spirometry (years, SD) 2.0 (2.7) 2.2 (3.0) 1.8 (2,2)
Therapy
- Short-acting beta2-agonists (SABA) 814(59.2) 458(58.9) 356(59.5)
- Long-acting beta2-agonists (LABA) 242(17.6) 131(16.9) 111 (18.6)
- Inhaled Corticosteroids (ICS) 397(28.9) 206(26.5) 191(31.9)
- Antihistamines 414(30.1) 230 (29.6) 184 (30.8)
- Leukotriene modifiers 272(19.8) 142 (18.3) 130 (21.7)
- LABA/ICS combinations 793 (57.7) 454(58.4) 339 (56.7)
- Omalizumab 5 (0.4) 3 (0.4) 2 (0.3)
- Systemic corticosteroids 187(13.6) 86 (11.1) 101(16.9)
- Methylxantines 58 (4.2) 21(2.7) 37 (6.2)
- Anticholinergic agents 128 (9.3) 54 (6.9) 74(12.4)
Other(phytodrugs, homeopathicagents,ecc) 20 (1.5) 7 (0.9) 13 (2.2)
Fig. 1 Subjects with uncontrolled asthma (ACT < 20) in Group A
(patients asking for asthma drug prescription renewal) and Group B
(patients with symptoms worsening)
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and in 35.7% increased the dose of the current medication.
As a whole, 63% of poorly controlled patients, not on a
controller therapy at the moment of recruitment, were
prescribed an anti-asthmatic treatment, either as a first
prescription or as a renewed prescription (data not
shown); therapy was changed or increased in 75.8% of un-
controlled patients already on treatment. In 61.1% of cases
GPs scheduled a new visit, whereas pulmonary/allergology
specialist visits or hospitalizations were prescribed in 26.2
and 0.7% of patients respectively (mostly in Group B). An
educational intervention (mainly on the use of inhalers)
was performed in 38% of patients. As a whole, interven-
tions undertaken by GPs were slightly more frequent in
Group B than in Group A.
In 14.7% of patients from Group B and in 44% of pa-
tients from Group A, GPs maintained the same level of
therapy despite an inadequate control of asthma. More
than 50% of uncontrolled patients in Group A increased
their treatment levels because of poor ACT score.
Discussion
The results of the ACTIS study show that the level of
asthma control in Italy and Spain, as assessed by ACT in
patients attending the GP’s clinic, is still poor. Although
some bias in the selection of the patients might be con-
sidered, almost 50% of the selected patients were still
uncontrolled. Nonetheless, the level of control in these
two countries, as well as in other European countries,
seems to be increased in the present study with respect
to the AIRE study, performed almost 10 years earlier [2].
This may be due to several reasons, including a larger
availability of effective anti-asthmatic medications re-
lated to the implementation of asthma guidelines, as
demonstrated in some countries [8], and to an increased
awareness of the disease in both physicians and patients
[9]. However, asthma control is still far from being opti-
mal and further improvement is desirable.
Poor adherence to daily drug therapy is recognized as
an important contributor to deterioration of asthma con-
trol, with increased morbidity and mortality [10]. Real life
studies report high rates of discontinuation of controller
treatments in asthmatic patients [11, 12]. The reasons for
non-adherence are varied and are likely to include insuffi-
cient inhaler technique, the complexity of the therapeutic
regimens (e.g. multiple daily dosing) as well as patient’s
beliefs about therapy, such as fear of adverse effects or the
perception that medication should be used in response to
symptoms more than on a regular basis [10, 13]. In keep-
ing with the latter observation, in our study a high per-
centage (>40%) of patients discontinued the treatment
when they felt better, suggesting a “symptoms, no asthma”
belief. Not surprisingly, treatment discontinuation was sig-
nificantly higher in group B (patients with symptom
worsening).
The most interesting finding in this study is that the
percentage of uncontrolled asthma is high not only in
patients attending GP’s clinic for worsening of asthma
symptoms, but also in patients attending GP’s clinic for
a simple renewal of drug prescriptions (77.8 and 28.6%,
respectively). While it is not surprising that almost 80%
of Group B patients were uncontrolled, the novel obser-
vation is that almost 30% of Group A patients were un-
controlled according to ACT. The reason why these
patients requested only a renewal of drug prescription
and not a reassessment of their asthma might be due to
a sort of “adaptation” to the constant presence of symp-
toms and/or limitations in daily life, which are consid-
ered inevitable and not susceptible of improvement. The
observation that more than half of uncontrolled patients
perceive their asthma as “under control” is in favor of
this hypothesis. Thus, in agreement with previous stud-
ies [2, 3], patients largely overestimate their asthma con-
trol level, thus precluding a more effective management
of the disease; the wrong conviction that “normal life”
cannot be attained may lead asthmatic patients to toler-
ate uncontrolled symptoms without asking the GP or
the pulmonary specialist for medical advice, in order to
improve asthma management.
An important practical implication of these data is that
GPs should systematically evaluate asthma control in all
Table 2 Relation between poor asthma control and
independent variables (univariate logistic regression); reference
group was patients with ACT ≥ 20
OR 95%CI P value
Age (10 year groups) 1.216 1.144 - 1.294 <0.0001
Asthma severity (mild/moderate/severe) 3.413 2.815 - 4.139 <0.0001
Asthma duration (5 years groups) 1.092 1.036 - 1.153 0.0013
Smoke (smokers vs no/ex) 1.474 1.124 - 1.932 0.0049
Country (Italy vs Spain) 1.469 1.187 - 1.818 0.0004
Gender (male vs female) 1.024 0.891 - 1.234 n.s.
Fig. 2 Patients who abandon the treatment when they feel better
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patients attending their clinic, even in those asking a
simple prescription renewal. Physician should also edu-
cate patients about the possibility of improving asthma
control with currently available drugs and therapeutic
strategies: this could lead to a better quality of life and a
lower consumption of socio-economic resources, as the
use of rescue medication, unscheduled visit to GPs or
pulmonary specialists, emergency department access or
hospitalization.
Patients included in this study are a good sample of asth-
matics well known to GPs: they are middle-aged, mainly fe-
male, with high percentages of current or ex-smokers. The
data disagree with the high prevalence of mild asthmatics
found in population-based epidemiological studies [14]
and reflect greater asthma severity in patients attending
the GP’s clinic. However, a limit of our study is the non-
random selection of the patients, which may have led to
inclusion of more severe patients. Also, the high rate of
intervention by GPS in patients who were uncontrolled by
ACT cannot be compared with a control group, not
included in the study design.
Our results are in keeping with those of previous studies
[15], showing that older age, asthma severity and duration
as well as smoking habits are associated with poor asthma
control. Increasing evidence suggests that the efficacy of
glucocorticoids is reduced in smoking-asthmatics [16] and
it has been reported that a high proportion of patients ad-
mitted to the emergency department for asthmatic exacer-
bation consists of smokers [17].
The finding of poor asthma control prompted GPs to
modify therapy in 75.8% of patients and to perform an
educational intervention in 39.2% of patients. On the
other hand, in a consistent proportion of uncontrolled
patients, GPs did not increase the level of anti-asthma
therapy. The reason of a lack of a “step-up” approach in
these cases is not clear. However, GINA Guidelines rec-
ommend an accurate assessment of the adherence and
of the inhalation technique before stepping-up [1], and
this might have been occurred also in this case. Fur-
thermore, in uncontrolled patients, GPs scheduled a
more stringent monitoring or required a pulmonologist
consultation. Thus, the extensive use of ACT may lead
GPs to a more active intervention to improve asthma
management, particularly in patients asking only for
Table 3 GP’s actions in poorly controlled asthmatic patients (ACT < 20)
Total Reasons for GP consultation
A: asking for asthma drugs
prescription renewal
B: seeking for medical advice
due to symptom worsening
N % N % N %
N. patients (n.d. = 1) 686 100 222 100.0 464 100.0
No change in therapy 166 24.2 98 44.1 68 14.7
Dose increase of the same therapy 245 35.7 76 34.2 169 36.4
Change of therapy 275 40.1 48 21.6 227 48.9
Other actions (N. patients = 687)
None 88 12.8 40 18.0 48 10.3
New visit scheduled 420 61.1 119 53.6 301 64.7
Specialistic visit required: 180 26.2 44 19.8 136 29.2
pneumologist 146 21.3 37 16.7 109 23.4
allergologist 33 4.8 8 3.6 25 5.4
other 2 0.3 . . 2 0.4
Emergency visit/hospitalization 5 0.7 1 0.5 4 0.9
Laboratory test 175 25.5 42 18.9 133 28.6
Education to inhaler device use 269 39.2 88 39.6 181 38.9
Other 24 3.5 8 3.6 16 3.4
Fig. 3 Actions undertaken by GPs in patients with poor asthma
control (ACT≤ 19)
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drug prescription renewal. In these patients, a more ac-
curate assessment of asthma control by using ACT may
detect poor adherence to therapy, poor inhaling tech-
nique, inadequate level of pharmacologic treatment, or
persistent exposure to asthma triggers.
Conclusions
The systematic use of ACT in asthmatic patients attend-
ing the GP’s clinic may detect high rates of uncontrolled
patients who underestimate their clinical conditions.
Inadequate control might partly be due to underestima-
tion of asthma symptoms and was associated with well
known risk factors (older age, asthma severity, smoking
habit). The recognition of poor asthma control induced
physicians to increase intervention in asthma care.
Therefore, a broader use of a simple and validated tool
like ACT may help GPs to implement of asthma guide-
lines in clinical practice, in order to improve disease
management and possibly reduce asthma morbidity.
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